$5.72
4.40% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Novavax, Inc. Target price 2025 - Analyst rating & recommendation

Novavax, Inc. Classifications & Recommendation:

Buy
57%
Hold
29%
Sell
14%

Novavax, Inc. Price Target

Target Price $16.43
Price $5.98
Potential
Number of Estimates 7
7 Analysts have issued a price target Novavax, Inc. 2026 . The average Novavax, Inc. target price is $16.43. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 4 Analysts recommend Novavax, Inc. to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Novavax, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Novavax, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 682.16 503.98
30.65% 26.12%
EBITDA Margin -26.90% -2.34%
29.22% 91.30%
Net Margin -28.93% -7.14%
67.21% 75.32%

7 Analysts have issued a sales forecast Novavax, Inc. 2025 . The average Novavax, Inc. sales estimate is

$504m
Unlock
. This is
26.12% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.1b 61.36%
Unlock
, the lowest is
$325m 52.36%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $682m 30.65%
2025
$504m 26.12%
Unlock
2026
$529m 4.97%
Unlock
2027
$304m 42.50%
Unlock
2028
$443m 45.65%
Unlock
2029
$419m 5.34%
Unlock

2 Analysts have issued an Novavax, Inc. EBITDA forecast 2025. The average Novavax, Inc. EBITDA estimate is

$-11.8m
Unlock
. This is
93.56% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$106m 157.99%
Unlock
, the lowest is
$-130m 29.13%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-183m 50.92%
2025
$-11.8m 93.56%
Unlock
2026
$146m 1,337.39%
Unlock
2027
$-113m 177.03%
Unlock

EBITDA Margin

2024 -26.90% 29.22%
2025
-2.34% 91.30%
Unlock
2026
27.62% 1,280.34%
Unlock
2027
-37.00% 233.96%
Unlock

7 Novavax, Inc. Analysts have issued a net profit forecast 2025. The average Novavax, Inc. net profit estimate is

$-36.0m
Unlock
. This is
83.01% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$451m 312.88%
Unlock
, the lowest is
$-209m 1.51%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-197m 77.26%
2025
$-36.0m 81.77%
Unlock
2026
$87.4m 343.00%
Unlock
2027
$-6.5m 107.46%
Unlock
2028
$111m 1,805.83%
Unlock
2029
$75.9m 31.73%
Unlock

Net Margin

2024 -28.93% 67.21%
2025
-7.14% 75.32%
Unlock
2026
16.53% 331.51%
Unlock
2027
-2.14% 112.95%
Unlock
2028
25.10% 1,272.90%
Unlock
2029
18.10% 27.89%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.23 -0.22
77.26% 82.11%
P/E negative
EV/Sales 0.58

7 Analysts have issued a Novavax, Inc. forecast for earnings per share. The average Novavax, Inc. EPS is

$-0.22
Unlock
. This is
83.33% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$2.81 312.88%
Unlock
, the lowest is
$-1.30 1.52%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.23 77.26%
2025
$-0.22 82.11%
Unlock
2026
$0.55 350.00%
Unlock
2027
$-0.04 107.27%
Unlock
2028
$0.69 1,825.00%
Unlock
2029
$0.47 31.88%
Unlock

P/E ratio

Current -4.52 425.58%
2025
-26.66 489.82%
Unlock
2026
10.97 141.15%
Unlock
2027
-147.22 1,442.02%
Unlock
2028
8.63 105.86%
Unlock
2029
12.63 46.35%
Unlock

Based on analysts' sales estimates for 2025, the Novavax, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.43 13.16%
2025
0.58 34.56%
Unlock
2026
0.55 4.74%
Unlock
2027
0.96 73.89%
Unlock
2028
0.66 31.34%
Unlock
2029
0.70 5.64%
Unlock

P/S ratio

Current 1.41 107.32%
2025
1.91 35.35%
Unlock
2026
1.82 4.73%
Unlock
2027
3.16 73.90%
Unlock
2028
2.17 31.34%
Unlock
2029
2.29 5.64%
Unlock

Current Novavax, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Dec 10 2024
HC Wainwright & Co.
Locked
Locked
Locked Nov 13 2024
HC Wainwright & Co.
Locked
Locked
Locked Nov 12 2024
Jefferies
Locked
Locked
Locked Oct 16 2024
B. Riley Securities
Locked
Locked
Locked Oct 10 2024
Jefferies
Locked
Locked
Locked Oct 02 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Dec 10 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 13 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 12 2024
Locked
Jefferies:
Locked
Locked
Oct 16 2024
Locked
B. Riley Securities:
Locked
Locked
Oct 10 2024
Locked
Jefferies:
Locked
Locked
Oct 02 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today